AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37858007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q4W
Number of subjects: 0
Study 37858007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q2W
Number of subjects: 0
Study 37858007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37858007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 37858032 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred eHealth intervention (phone support and interactive digital platform)
Number of subjects: 209
Study 37858032 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 209
Study 37858103 — intervention group
Group type: EXPERIMENTAL
Intervention: New birthing room design
Number of subjects: 21
Study 37858132 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for OMD
Number of subjects: 32
Study 37858161 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely supervised home-based exercise program (12 weeks, 2 sessions/week for first 6 weeks, 3 sessions/week for remaining 6 weeks)
Number of subjects: 0
Study 37858161 — intervention group
Group type: COMPARATOR
Intervention: Recommendations for physical activity based on the Physical Activity Guide for the Brazilian Population
Number of subjects: 0
Study 37858184 — intervention group
Group type: EXPERIMENTAL
Intervention: GT90001 plus nivolumab
Number of subjects: 20
Study 37858195 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA from ascites
Number of subjects: 20
Study 37858195 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNA analysis on ascitic cfDNA
Number of subjects: 20
Study 37858195 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNA profiles on ascites and tumor
Number of subjects: 20
Study 37858212 — intervention group
Group type: EXPERIMENTAL
Intervention: RPP group (low-dose and low-concentration iodine contrast medium)
Number of subjects: 52
Study 37858212 — intervention group
Group type: EXPERIMENTAL
Intervention: RPP group
Number of subjects: 52
Study 37858212 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 52
Study 37858247 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) supplementation, 4 IU/day subcutaneous from the beginning of ovarian stimulation (OS) to the trigger day.
Number of subjects: 412
Study 37858247 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) supplementation
Number of subjects: 412
Study 37858247 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH supplementation)
Number of subjects: 412
Study 37858249 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, group-based Unified Protocol (UP) intervention
Number of subjects: 180
Study 37858249 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 180
Study 37858328 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab (6 and 3 mg/kg on days 1 and 2, 1·5 mg/kg weekly until week 12)
Number of subjects: 47
Study 37858328 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 47
Study 37858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV followed by MVA-BN-Filo (Ebola vaccine group)
Number of subjects: 108
Study 37858585 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal quadrivalent conjugate vaccine (control group)
Number of subjects: 108
Study 37858599 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased or decreased upper airway volume (UAV) measured in 3-dimensional computed tomography.
Number of subjects: 54
Study 37858617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil aromatherapy
Number of subjects: 112
Study 37858617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (jojoba oil)
Number of subjects: 112
Study 37858720 — intervention group
Group type: EXPERIMENTAL
Intervention: LVIS/LVIS Jr devices
Number of subjects: 130
Study 37858724 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 status at gestational weeks 18 and 36
Number of subjects: 136
Study 37858724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant vitamin B12 status at 3 and 6 months
Number of subjects: 136
Study 37858724 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding status
Number of subjects: 136
Study 37858724 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal supplement use during pregnancy
Number of subjects: 136
Study 37858758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resection (HR)
Number of subjects: 20
Study 37858758 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection (CR)
Number of subjects: 20
Study 37858867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy after 3-5 days of IV therapy
Number of subjects: 165
Study 37858867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 165
Study 37858867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy
Number of subjects: 165
Study 37859587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 102
Study 37859587 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 102
Study 37859647 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band green light (NbGL) treatment during migraine attacks
Number of subjects: 698
Study 37859672 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab 200/300 mg
Number of subjects: 0
Study 37859748 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose ahaMSCs-Exos (intranasally administered two times per week for 12 weeks)
Number of subjects: 0
Study 37859748 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37859768 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS plus cognitive intervention
Number of subjects: 70
Study 37860154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training programme in individual practice at home (n=53)
Number of subjects: 159
Study 37860154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training programme in group practice in a gymnasium (n=53)
Number of subjects: 159
Study 37860154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training programme in group practice in an enriched environment (n=53)
Number of subjects: 159
Study 37860154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training programme (all groups)
Number of subjects: 159
Study 37860154 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 159
Study 37860278 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT141 mRNA-LNP
Number of subjects: 0
Study 37860278 — intervention group
Group type: COMPARATOR
Intervention: IMAB362/Zolbetuximab
Number of subjects: 0
Study 37860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual Cups (MC)
Number of subjects: 4137
Study 37860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash Transfers (CCT)
Number of subjects: 4137
Study 37860578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MC and CCT
Number of subjects: 4137
Study 37860578 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4137
Study 37860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab 15 mg/kg every 4 weeks
Number of subjects: 14
Study 37861217 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 328
Study 37861217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 37861217 — intervention group
Group type: COMPARATOR
Intervention: Teplizumab and Placebo
Number of subjects: 328
Study 37861218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarlatamab 10 mg every 2 weeks
Number of subjects: 220
Study 37861218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarlatamab 100 mg every 2 weeks
Number of subjects: 220
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E at 1.00 mg/kg
Number of subjects: 93
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E in total population
Number of subjects: 93
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E in CPI-exposed subgroup
Number of subjects: 93
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E at doses of ≥0.75 mg/kg
Number of subjects: 93
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E at doses of 0.50 to 1.25 mg/kg
Number of subjects: 93
Study 37861407 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS15E
Number of subjects: 93
Study 37861675 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant nevirapine
Number of subjects: 2016
Study 37861675 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg positivity
Number of subjects: 2016
Study 37861675 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV active drugs (HBV-ARV)
Number of subjects: 2016
Study 37861675 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ARV
Number of subjects: 2016
Study 37861683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic choice HIV prevention (DCP) intervention
Number of subjects: 403
Study 37861683 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 403
Study 37861929 — intervention group
Group type: EXPERIMENTAL
Intervention: Q.Clear algorithm with β-factors ranging from 100 to 3500
Number of subjects: 0
Study 37861988 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Behavioral Therapy
Number of subjects: 0
Study 37861988 — intervention group
Group type: COMPARATOR
Intervention: Standard Community Care
Number of subjects: 0
Study 37861993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab, Paclitaxel, and Carboplatin (ABCP)
Number of subjects: 228
Study 37861993 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus Carboplatin or Cisplatin (PC)
Number of subjects: 228
Study 37862013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and Velpatasvir 100 mg for 12 weeks (2-week starter pack provided at diagnosis)
Number of subjects: 492
Study 37862013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir treatment
Number of subjects: 492
Study 37862075 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisepill adherence monitor for 3 months with options for SMS reminders, social supporter, or alarm reminder.
Number of subjects: 15
Study 37862075 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisepill adherence monitor for 3 months.
Number of subjects: 15
Study 37862083 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary allied health care (dietitians, exercise therapists, occupational therapists, physical therapists, speech and language therapists)
Number of subjects: 1451
Study 37862083 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary allied health care
Number of subjects: 1451
Study 37862103 — intervention group
Group type: EXPERIMENTAL
Intervention: Healium
Number of subjects: 327
Study 37862103 — intervention group
Group type: COMPARATOR
Intervention: Healing Choices
Number of subjects: 327
Study 37862324 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills to Enhance Positivity (STEP)
Number of subjects: 0
Study 37862324 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 0
Study 37862463 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 2335
Study 37862463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2335
Study 37862463 — intervention group
Group type: EXPERIMENTAL
Intervention: None (pretrial population)
Number of subjects: 2335
Study 37862670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) app
Number of subjects: 449
Study 37862670 — intervention group
Group type: COMPARATOR
Intervention: Health education sham app
Number of subjects: 449
Study 37862791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 317
Study 37862823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omega-3 fatty acids capsules (1 g daily)
Number of subjects: 70
Study 37862823 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (control group)
Number of subjects: 70
Study 37862832 — intervention group
Group type: EXPERIMENTAL
Intervention: CANKADO-active arm (supported by CANKADO PRO-React)
Number of subjects: 0
Study 37862832 — intervention group
Group type: COMPARATOR
Intervention: CANKADO-inform arm (drug intake documentation only)
Number of subjects: 0
Study 37863080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusfertide (10 mg once weekly for 24 weeks)
Number of subjects: 16
Study 37863080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusfertide
Number of subjects: 16
Study 37863084 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous insulin icodec
Number of subjects: 582
Study 37863084 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 582
Study 37863088 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR T cells
Number of subjects: 81
Study 37863088 — intervention group
Group type: EXPERIMENTAL
Intervention: CD22-directed CAR T cells
Number of subjects: 81
Study 37863158 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid prescription protocol (3-10 tablets of 5 mg oxycodone upon discharge)
Number of subjects: 133
Study 37863158 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive opioid prescription protocol (no opioid prescription unless requested)
Number of subjects: 133
Study 37863158 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid prescription protocol
Number of subjects: 133
Study 37863158 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive opioid prescription protocol
Number of subjects: 133
Study 37863161 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37863160 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate)
Number of subjects: 241
Study 37863160 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 241
Study 37863195 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg intrathecal morphine
Number of subjects: 72
Study 37863195 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mcg intrathecal morphine
Number of subjects: 72
Study 37863195 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mcg intrathecal morphine
Number of subjects: 72
Study 37863268 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-level income-generating agricultural intervention
Number of subjects: 62
Study 37863268 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 62
Study 37863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations to naloxone provision during the COVID-19 pandemic
Number of subjects: 134
Study 37863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations to OTC syringe sales during the COVID-19 pandemic
Number of subjects: 134
Study 37863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adaptations perceived by pharmacy staff
Number of subjects: 134
Study 37863418 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen reserve index-guided oxygen titration
Number of subjects: 92
Study 37863418 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen titration based on pulse oximetry
Number of subjects: 92
Study 37863590 — intervention group
Group type: COMPARATOR
Intervention: Intracranial pressure monitoring only
Number of subjects: 318
Study 37863590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intracranial pressure and brain tissue oxygen pressure monitoring
Number of subjects: 318
Study 37863608 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 101
Study 37863608 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 101
Study 37863608 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 101
Study 37863785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry heat application
Number of subjects: 117
Study 37863785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cold application
Number of subjects: 117
Study 37863785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 37863878 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TME with Denonvilliers' fascia preservation (L-DVF-P)
Number of subjects: 262
Study 37863878 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TME with Denonvilliers' fascia resection (L-DVF-R)
Number of subjects: 262
Study 37863916 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg on day 1) plus nab-paclitaxel (125 mg/m2) and epirubicin (dosage not specified)
Number of subjects: 0
Study 37864049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus concurrent chemo-radiotherapy (CCRT)
Number of subjects: 201
Study 37864049 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus concurrent chemo-radiotherapy (CCRT)
Number of subjects: 201
Study 37864139 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home computerized executive function training for 12 weeks
Number of subjects: 0
Study 37864139 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 37864152 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy (SABR) in addition to standard of care (Arm 2)
Number of subjects: 270
Study 37864152 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy (Arm 1)
Number of subjects: 270
Study 37864156 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 32
Study 37864195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid-soaked gelatin sponge
Number of subjects: 63
Study 37864209 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 50
Study 37864209 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 50
Study 37864252 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) therapy through an immersive VR garden intervention
Number of subjects: 83
Study 37864252 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional post-stroke rehabilitation program without VR therapy)
Number of subjects: 83
Study 37864252 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison in the experimental group (women)
Number of subjects: 83
Study 37864258 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for caregivers of hospitalized children (CommunityRx-Hunger)
Number of subjects: 639
Study 37864258 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for caregivers of community-residing people with dementia (CommunityRx-Dementia)
Number of subjects: 639
Study 37864258 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for both trials
Number of subjects: 639
Study 37864269 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRST (transdiagnostic intervention built on five empirically supported principles of change)
Number of subjects: 212
Study 37864269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study 37864281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (0.05 to 0.2 mg/kg, oral, once daily in the morning)
Number of subjects: 13
Study 37864313 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 429
Study 37864337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab
Number of subjects: 718
Study 37864337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib
Number of subjects: 718
Study 37864337 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance
Number of subjects: 718
Study 37864379 — intervention group
Group type: EXPERIMENTAL
Intervention: beinaglutide alone
Number of subjects: 68
Study 37864379 — intervention group
Group type: EXPERIMENTAL
Intervention: insulin glargine (IGlar)
Number of subjects: 68
Study 37864379 — intervention group
Group type: EXPERIMENTAL
Intervention: beinaglutide combined with insulin glargine (IGlar)
Number of subjects: 68
Study 37864583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional stabilization and medical treatment during hospitalization (mean hospitalization: 6 weeks)
Number of subjects: 33
Study 37864583 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge assessments after nutritional stabilization
Number of subjects: 33
Study 37864583 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments up to 6 months after discharge
Number of subjects: 33
Study 37864592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.11 GBq/cycle
Number of subjects: 13
Study 37864592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.85 GBq/cycle
Number of subjects: 13
Study 37864592 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.59 GBq/cycle
Number of subjects: 13
Study 37864596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 58
Study 37864596 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy (Control)
Number of subjects: 58
Study 37864646 — intervention group
Group type: EXPERIMENTAL
Intervention: PT2385 (800 mg b.i.d.)
Number of subjects: 24
Study 37864735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Anastomosis Duodenal Switch (SADI-S)
Number of subjects: 62
Study 37864735 — intervention group
Group type: COMPARATOR
Intervention: Classic Duodenal Switch (DS)
Number of subjects: 62
Study 37864852 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 128
Study 37864852 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 128
Study 37864885 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-(3-1H-indazolyl)amino quinazoline derivatives (compounds 27e, 27g, 27i, and 27j)
Number of subjects: 0
Study 37865043 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg vaccine
Number of subjects: 216
Study 37865043 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg vaccine
Number of subjects: 216